[go: up one dir, main page]

WO2014006738A1 - Dispositif de traitement pour traiter l'intérieur d'une lumière d'organisme - Google Patents

Dispositif de traitement pour traiter l'intérieur d'une lumière d'organisme Download PDF

Info

Publication number
WO2014006738A1
WO2014006738A1 PCT/JP2012/067291 JP2012067291W WO2014006738A1 WO 2014006738 A1 WO2014006738 A1 WO 2014006738A1 JP 2012067291 W JP2012067291 W JP 2012067291W WO 2014006738 A1 WO2014006738 A1 WO 2014006738A1
Authority
WO
WIPO (PCT)
Prior art keywords
substance
treatment device
deformation
blood vessel
coated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2012/067291
Other languages
English (en)
Japanese (ja)
Inventor
石井直樹
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Terumo Corp
Original Assignee
Terumo Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terumo Corp filed Critical Terumo Corp
Priority to PCT/JP2012/067291 priority Critical patent/WO2014006738A1/fr
Publication of WO2014006738A1 publication Critical patent/WO2014006738A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0074—Dynamic characteristics of the catheter tip, e.g. openable, closable, expandable or deformable
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0082—Catheter tip comprising a tool
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/00491—Surgical glue applicators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
    • A61B17/00—Surgical instruments, devices or methods
    • A61B17/00234—Surgical instruments, devices or methods for minimally invasive surgery
    • A61B2017/00292—Surgical instruments, devices or methods for minimally invasive surgery mounted on or guided by flexible, e.g. catheter-like, means
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
    • A61F2/00—Filters implantable into blood vessels; Prostheses, i.e. artificial substitutes or replacements for parts of the body; Appliances for connecting them with the body; Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/82—Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
    • A61F2/94—Stents retaining their form, i.e. not being deformable, after placement in the predetermined place
    • A61F2/945—Stents retaining their form, i.e. not being deformable, after placement in the predetermined place hardenable, e.g. stents formed in situ
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/0067—Catheters; Hollow probes characterised by the distal end, e.g. tips
    • A61M25/0082—Catheter tip comprising a tool
    • A61M2025/0096—Catheter tip comprising a tool being laterally outward extensions or tools, e.g. hooks or fibres

Definitions

  • the present invention relates to a treatment device for a living body lumen that applies a substance to be coated on the inner surface of a living body lumen.
  • a technique for delivering a therapeutic device to a lesion in a living organ for example, a blood vessel, a bile duct, a trachea, an esophagus, a urethra, a nasal cavity, or other organs
  • a therapeutic device for treating a stenosis that is a lesion of a blood vessel includes a stent (including a drug eluting stent: DES), a drug eluting balloon catheter (DEB), or other prosthesis that pushes the blood vessel wall from the inside. Things are used.
  • an ablation device that can be delivered via a blood vessel is used as a therapeutic device, and a treatment for cutting (ablation) a nerve inside a blood vessel (for example, a renal artery) is sometimes performed.
  • the treatment device contacts or expands on the thickened blood vessel wall (intima), whereby the elastic plate in the intima is cracked or ruptured, or the blood vessel with the contact of the treatment device It has been confirmed that the walls are inflamed and damaged.
  • a thrombus is generated in the blood vessel to embolize the peripheral blood vessel, or restenosis occurs at the treatment site.
  • improvement of the treatment of lesions has been attempted by applying the composition disclosed in US Patent Application Publication No. 2011/0077216 to the treated blood vessel wall.
  • US Patent Application Publication No. 2011/0077216 discloses a gel adhesive called alginate-catechol.
  • the catechol group reacts with the blood vessel wall, and the alginate is cross-linked by Ca 2+ present at a high concentration at the inflammatory site. For this reason, an adhesive agent will gelatinize in a short time and can coat the blood vessel wall after a treatment favorably.
  • the treatment device disclosed in U.S. Patent Application Publication No. 2011/0077216 is configured to discharge adhesive from the side surface of a catheter formed in a long and thin shape, and the influence of blood flowing in the blood vessel is reduced. Receive a lot.
  • blood near the center flows faster than blood near the blood vessel wall, so when a solution containing an adhesive substance is discharged from the side of the treatment device located on the axis of the blood vessel, The solution containing the adhesive substance is poured, and it becomes difficult to attach a sufficient amount of the adhesive substance to the treatment target.
  • the adhesive substance is discharged only from the discharge port formed at a predetermined position of the catheter, it is likely to adhere unevenly to the blood vessel wall.
  • the present invention has been made to solve the above-described problem, and can reliably apply a substance to be applied to a desired treatment target in a living body lumen, thereby favorably treating the living body lumen. It is an object of the present invention to provide a biological intraluminal treatment device that can be used.
  • a treatment device for living body lumen includes a long shaft inserted into a living body lumen, a proximal end side supported by the shaft, and a distal end side supported by the shaft.
  • a support part that can be expanded and contracted in a direction perpendicular to the axial direction of the support part, and is provided to be deformable on the distal end side of the support part.
  • a deformable application part having a discharge port which is located in the vicinity of the inner surface of the living body lumen and can discharge the substance to be applied.
  • the deformation application part having the discharge port for discharging the substance to be applied is provided at the distal end part of the support part that can be expanded and contracted in the direction orthogonal to the axial direction of the shaft, so that the living body lumen to be delivered
  • the deformation application portion can be easily expanded / contracted in the radial direction. Therefore, it is possible to efficiently perform the operation of reducing the diameter of the deformation application portion and delivering the inside of the living body lumen, and expanding the deformation application portion to contact or approach the inner surface of the living body lumen.
  • the discharge port is present in the vicinity of the inner surface of the biological lumen, applying the substance to be coated from this discharge port is hardly affected by the fluid flowing in the biological lumen, The substance to be coated can be reliably attached to the treatment target on the inner surface of the living body lumen.
  • the deformation application part may be enlarged / reduced following the expansion / contraction of the support part.
  • transformation application part can be easily expanded / contracted within a biological lumen.
  • the support unit and the deformation application unit are accommodated, and the inside of the living body lumen can be delivered, and an outer tube that can move forward and backward with respect to the support unit and the deformation application unit is provided. It is preferable that the distal end side is contracted by being restricted by the outer tube while being accommodated in the outer tube, and is expanded by an elastic restoring force when exposed from the outer tube.
  • the support portion contracts by the outer tube and is exposed from the outer tube, the support portion expands by the elastic restoring force, so that the outer diameter of the deformation application portion is easily switched based on the forward / backward movement of the outer tube. be able to. Then, the extension amount of the tip of the support portion is adjusted by the exposure amount from the outer tube, and regardless of the thickness of the biological lumen, the deformation application portion is appropriately pressed on the inner surface of the biological lumen. It can be contacted by pressure.
  • the deformation application portion is formed in a flexible ring shape, and the discharge port is located on the distal end surface side and the radially outer side of the deformation application portion, and in the circumferential direction of the deformation application portion. It is good to provide a plurality along.
  • the discharge port is positioned on the distal end surface side and the radially outer side of the deformation application portion, the discharge port is not blocked by the inner surface of the living body lumen, and a sufficient amount of the substance to be applied is applied. be able to.
  • the substance to be applied can be uniformly discharged from the plurality of discharge ports and attached to the treatment target.
  • the deformation application part has a coating substance passage that circulates in the interior and communicates with the discharge port, and has a coating substance supply path that communicates with the coating substance passage and can supply the coating substance. It is preferable that they are connected.
  • the shaft has a coating substance distribution lumen extending in the axial direction inside, and the deformation coating section has a coating substance passage that circulates inside and communicates with the discharge port, and the support section.
  • the coating substance passage of the deformation coating portion communicates with the coating substance distribution lumen of the shaft via the communication passage of the support portion, so that the deformation coating portion is coated through the coating substance distribution lumen inside the shaft.
  • the coating material can be easily guided and the coating material can be discharged from the discharge port.
  • the surface of the deformation application part may be coated with a lubricating coating agent.
  • the surface of the deformation application portion is coated with the lubricity coating agent, so that the deformation application portion is arranged in the axial direction of the biological lumen in a state where the deformation application portion is in contact with the inner surface of the biological lumen. Can be slid smoothly.
  • the deformation application portion has contrast, the operator can accurately grasp the position where the application of the substance to be applied is started.
  • the substance to be coated can be reliably attached to a desired treatment target in the living body lumen, and thus the living body lumen can be favorably treated.
  • FIG. 2A is a partial front view showing the unfolded state of the frame and deformation application portion of FIG. 1
  • FIG. 2B is a partial side view showing the unfolded state of the frame and deformation application portion of FIG. 1, and FIG. It is a partial side view which shows the accommodation state of the flame
  • FIG. 2D is a partial side view which shows the expansion
  • FIG. 3A is a main part front view showing a treatment device according to a first configuration example
  • FIG. 3A is a main part front view showing a treatment device according to a first configuration example
  • FIG. 3B is a main part perspective view showing a treatment device according to a second configuration example
  • FIG. 3C is a third configuration example. It is a principal part front view which shows the treatment device which concerns on FIG. 3
  • FIG. 3D is a principal part front view which shows the treatment device which concerns on a 4th structural example.
  • FIG. 4A is a main part side view showing a treatment device according to a fifth configuration example
  • FIG. 4B is a main part side view showing a treatment device according to a sixth configuration example
  • FIG. 4C is a seventh configuration example.
  • FIG. 4D is a side view of an essential part showing a treatment device according to an eighth configuration example.
  • FIG. 5A is a first explanatory diagram showing an operation procedure using the treatment device of FIG. 1, FIG.
  • FIG. 1 is a perspective view showing an overall configuration of a treatment device 10 according to the present embodiment.
  • This intraluminal treatment device 10 (hereinafter, also simply referred to as the treatment device 10) is used to treat a lesion in a blood vessel by a treatment method (intervention) in which a catheter is inserted into a blood vessel through a small hole opened in the skin.
  • the present therapeutic device 10 is used in combination with a treatment of a lesioned portion (a narrowed portion or a portion where a blood vessel wall is weakened) with a balloon catheter, a stent, or an atherectomy device, or a blood vessel treatment with an ablation device. Used to apply the substance to be applied to the later blood vessel wall.
  • the treatment device 10 is delivered and the substance to be applied is applied to the treatment site.
  • the treatment device 10 is delivered to apply the substance to be coated around the placement site of the stent.
  • the therapeutic device 10 is delivered and the substance to be applied is applied to the treatment site.
  • the sympathetic ablation treatment after a treatment for cutting the sympathetic nerve passing through the inside of the blood vessel wall is performed, the therapeutic device 10 is delivered and the substance to be applied is applied to the blood vessel wall at the treatment site.
  • the treatment device 10 that applies the substance to be applied after removing the atheroma (treatment target X) generated in the blood vessel wall B in the blood vessel A will be described representatively (see FIGS. 5A to 5C).
  • the treatment device 10 is not limited to the above procedure and can be used for various procedures, and various biological lumens (for example, bile duct, trachea, esophagus, urethra, nasal cavity, other organs, etc.). Of course, it can be applied to internal therapy.
  • the treatment device 10 includes a shaft 12, a support portion 16 connected to the distal end portion of the shaft 12, a deformation application portion 18 provided at the distal end portion of the support portion 16, the support portion 16 and the deformation. And a sheath 20 capable of accommodating the application portion 18 and delivering the inside of the blood vessel A.
  • the support portion 16 is constituted by a plurality (six in FIG. 1) of frames 14.
  • the deformation application unit 18 is provided with a plurality of discharge ports 22 through which the substance to be applied can be discharged onto the treatment target X in the blood vessel A.
  • the shaft 12 is a solid rod member, is formed to have an outer diameter that can be accommodated in the sheath 20, and extends linearly with a sufficient length so that the deformation application portion 18 can reach the treatment target X.
  • Six frames 14 are connected to the distal end portion of the shaft 12, and the shaft 12 and the frame 14 (and the deformation applying portion 18) can operate integrally with the blood vessel A.
  • a hub 24 having a diameter larger than that of the shaft 12 is provided at the base end portion of the shaft 12 so as to be easily grasped by the operator.
  • the hub 24 includes a movable portion 26 on the distal end side to which the shaft 12 is coupled, and a fixed portion 28 on the proximal end side that surrounds the movable portion 26 so that the movable portion 26 can be accommodated, and the movable portion 26 moves forward and backward with respect to the fixed portion 28.
  • the shaft 12 can be moved forward and backward.
  • the advance / retreat movement of the movable portion 26 can be performed by the actuator 30 in addition to the operator.
  • this actuator 30 for example, an external drive device disclosed in Japanese Patent Application Laid-Open No. 2011-152274 filed earlier by the present applicant can be suitably applied.
  • an applied substance supply port 32 is formed in the fixed portion 28, and the applied substance supply port 32 is connected to a tube 34 that passes inside and outside the hub 24. Further, the substance to be coated supply port 32 is connected to a syringe (not shown) that supplies the substance to be coated based on an operation of an operator or the like.
  • the tube 34 is provided along the side surface of the shaft 12 from the hub 24 and extends in the distal direction of the treatment device 10.
  • An application substance supply path 36 through which an application substance can flow is formed through the tube 34, and a base end side of the application substance supply path 36 is connected to a syringe via an application substance supply port 32. Yes.
  • the tip of the tube 34 is branched into three small diameter tubes 34a at a position where the shaft 12 and the six frames 14 are connected.
  • the three small-diameter tubes 34a extend in the distal direction, and their end portions are connected to the ring-shaped deformation application portion 18 at equal intervals (120 ° intervals).
  • the substance to be coated supply path 36 extends through each small-diameter tube 34 a and communicates with the substance to be coated channel 38 of the deformation coating unit 18.
  • the substance to be coated supplied from the syringe to the substance to be coated supply path 36 via the substance to be coated supply port 32 is guided from the substance to be coated supply path 36 to the substance path 38 to be coated on the tip side and is discharged from the discharge port 22. It is discharged into the blood vessel A.
  • the substance to be coated examples include alginate-catechol that exhibits a strong adhesive force to the blood vessel wall B.
  • the alginate-catechol gels in the blood vessel A in a short time, and well coats the blood vessel wall B after the treatment. For this reason, it is possible to prevent the restenosis and the thrombus from occurring in the treatment target X while protecting the inflammation and the like generated in the treatment target X.
  • the material to be applied is not limited to alginate-catechol, and examples thereof include polysaccharides such as heparin and hyaluronic acid, betaine-based polymers, and catechol-modified products of polyethylene glycol.
  • various drugs including biological and physiologically active substances can be applied simultaneously.
  • a biological physiologically active substance that suppresses restenosis by adhering to a treatment site in the blood vessel A may be applied.
  • biologically bioactive substances include anticancer agents, immunosuppressive agents, antibiotics, anti-rheumatic agents, antithrombotic agents, antihyperlipidemic agents, ACE inhibitors, calcium antagonists, integrin inhibitors, antiallergies.
  • Agents antioxidants, GPIIbIIIa antagonists, retinoids, flavonoids, carotenoids, lipid improvers, DNA synthesis inhibitors, tyrosine kinase inhibitors, antiplatelet agents, vascular smooth muscle growth inhibitors, anti-inflammatory agents, lipoprotein-related phospholipase inhibition Agents, biological materials, interferons, NO production promoting substances, and the like.
  • anticancer agent for example, vincristine sulfate, vinblastine sulfate, vindesine sulfate, irinotecan hydrochloride, paclitaxel, docetaxel hydrate, methotrexate, cyclophosphamide and the like are preferable.
  • immunosuppressive agent for example, sirolimus (rapamycin), tacrolimus hydrate, azathioprine, cyclosporine, mycophenolate mofetil, gusperimus hydrochloride, mizoribine and the like are preferable.
  • antibiotic for example, mitomycin C, doxorubicin hydrochloride, actinomycin D, daunorubicin hydrochloride, idarubicin hydrochloride, pirarubicin hydrochloride, aclarubicin hydrochloride, epirubicin hydrochloride, pepromycin sulfate, dinostatin styramer and the like are preferable.
  • antirheumatic agent for example, sodium gold thiomalate, penicillamine, lobenzalit disodium and the like are preferable.
  • antithrombotic agent for example, heparin, ticlopidine hydrochloride, hirudin and the like are preferable.
  • an HMG-CoA reductase inhibitor or probe is preferable.
  • the HMG-CoA reductase inhibitor for example, cerivastatin sodium, atorvastatin, nisvastatin, pitavastatin, fluvastatin sodium, simvastatin, lovastatin, pravastatin sodium and the like are preferable.
  • ACE inhibitor for example, quinapril hydrochloride, perindopril erbumine, trandolapril, cilazapril, temocapril hydrochloride, delapril hydrochloride, enalapril maleate, lisinopril, captopril and the like are preferable.
  • calcium antagonist for example, nifedipine, nilvadipine, diltiazem hydrochloride, benidipine hydrochloride, nisoldipine and the like are preferable. More specifically, for example, tranilast is preferable as the antiallergic agent.
  • the physiologically active substance may include only one type of the biologically physiologically active substances exemplified above, or may include two or more different biologically physiologically active substances. When two or more kinds of biological physiologically active substances are included, the combination may be appropriately selected from the biologically physiologically active substances exemplified above as necessary.
  • the deformation application part 18 having the discharge port 22 for discharging the substance to be applied is formed in a ring (ring) shape that can be expanded and contracted in a direction (radial direction) perpendicular to the axial direction of the shaft 12.
  • the expansion / contraction of the deformation application portion 18 is realized by the six frames 14 that support the deformation application portion 18 on the base end side.
  • FIG. 2A is a partial front view showing a developed state of the frame 14 and the deformation application unit 18 in FIG. 1
  • FIG. 2B is a partial side view showing a development state of the frame 14 and the deformation application unit 18 in FIG.
  • FIG. 2C is a partial side view showing a housing state of the frame 14 and the deformation application part 18 of FIG. 1
  • FIG. 2D is a partial side view showing a developed state of the deformation application part 18 in the thin blood vessel A1.
  • the six frames 14 extend from the connecting portion of the shaft 12 toward the distal end and radially outward in a natural state exposed from the sheath 20. These six frames 14 are provided at equal intervals (60 ° intervals in the front view) along the axis of the shaft 12 in the front view and extend so as to spread radially, and the distal ends of the six frames 14 are most spaced apart from each other. ing.
  • the deformation application part 18 is attached so as to bridge the tip part of each frame 14.
  • the six frames 14 are connected to the shaft 12 so as to have a predetermined elastic force, and the tip portions of the six frames 14 are elastically close to each other. Therefore, it is preferable that the connection part of the six frames 14 and the shaft 12 is integrated in a metallic manner by processing such as continuous connection by casting or cutting, or welding. Thereby, the frame 14 is elastically supported with respect to the shaft 12 so that the inclination angle (inclination with respect to the axial direction of the shaft 12) forms a predetermined angle in a natural state.
  • the shaft 12 and the frame 14 are made of a metal having shape memory property.
  • materials include pseudoelastic alloys (including superelastic alloys) such as Ni-Ti alloys (naitinol), shape memory alloys, stainless steel (for example, SUS304, SUS303, SUS316, SUS316L, SUS316J1, SUS316J1L, SUS405, SUS430, SUS434, SUS444, SUS429, SUS430F, SUS302 etc., all SUS varieties), cobalt alloys, noble metals such as gold and platinum, tungsten alloys, carbon materials (including piano wires), etc. Can be mentioned.
  • the material is not particularly limited as long as the tip of the frame 14 can be elastically swung, and a resin such as a polymer material may be used.
  • the polymer material include polyolefin (eg, polyethylene, polypropylene, polybutene, ethylene-propylene copolymer, ethylene-vinyl acetate copolymer, ionomer, or a mixture of two or more thereof), polyvinyl chloride, polyamide. , Polyamide elastomers, polyesters, polyester elastomers, polyurethanes, polyurethane elastomers, polyimides, fluororesins, and the like, or a mixture thereof, or a combination of the above two or more polymer materials.
  • a shape memory resin that can change its shape (for example, increase its diameter) at body temperature may be used. In this case, it is possible to maintain the state in which the deformation application portion 18 is in contact with the lumen wall without further damaging the lumen wall, and to more reliably suppress damage to the blood vessel wall B and the like. Expected to be.
  • the radial shape of the six frames 14 according to the present embodiment is maintained with a relatively weak elastic force, and is easily elastically deformed by coming into contact with the sheath 20.
  • the tip portions of the six frames 14 act so as to be close to each other.
  • the deformation application portion 18 is also radially contracted and accommodated together in the sheath 20.
  • an elastic restoring force acts on each frame 14 so that the tip portions are separated from each other.
  • transformation application part 18 is also expanded to radial direction outer side.
  • the deformation application portion 18 is adjusted by adjusting the displacement amount of the sheath 20. It can be brought into contact with the blood vessel wall B1 with a predetermined pressing force. In this case, the deformation application unit 18 develops with a small outer diameter, but when the material to be applied is supplied, the deformation application unit 18 swells quickly and can discharge the material to be applied from the discharge port 22. Further, the sheath 20 and the shaft 12 may be provided with an adjustment mechanism capable of adjusting the displacement amount of the sheath 20 in a stepwise manner, that is, capable of changing the outer diameter of the deformation applying unit 18 in a stepwise manner.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
PCT/JP2012/067291 2012-07-06 2012-07-06 Dispositif de traitement pour traiter l'intérieur d'une lumière d'organisme Ceased WO2014006738A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/JP2012/067291 WO2014006738A1 (fr) 2012-07-06 2012-07-06 Dispositif de traitement pour traiter l'intérieur d'une lumière d'organisme

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2012/067291 WO2014006738A1 (fr) 2012-07-06 2012-07-06 Dispositif de traitement pour traiter l'intérieur d'une lumière d'organisme

Publications (1)

Publication Number Publication Date
WO2014006738A1 true WO2014006738A1 (fr) 2014-01-09

Family

ID=49881527

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2012/067291 Ceased WO2014006738A1 (fr) 2012-07-06 2012-07-06 Dispositif de traitement pour traiter l'intérieur d'une lumière d'organisme

Country Status (1)

Country Link
WO (1) WO2014006738A1 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526506B2 (en) 2013-07-29 2016-12-27 Terumo Kabushiki Kaisha Device for treating lumen of living body
US20170216561A1 (en) * 2014-10-13 2017-08-03 Emory University Delivery Devices, Systems and Methods for Delivering Therapeutic Materials
WO2018034922A1 (fr) 2016-08-16 2018-02-22 Ethicon, Inc. Pointes de pulvérisation pour distribution simultanée multidirectionnelle de fluides dissemblables
WO2021102191A3 (fr) * 2019-11-19 2021-06-24 Papilio Medical, Inc. Système de cathéter destiné à être mis en prise avec un dispositif médical implanté

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002238909A (ja) * 2001-02-07 2002-08-27 Interventional Technol Inc 脈管治療システム
JP2004049545A (ja) * 2002-07-19 2004-02-19 Terumo Corp 脈管内血液フィルタ
JP2004533277A (ja) * 2001-02-09 2004-11-04 エンドルミナル セラピューティクス， インコーポレイテッド 壁内療法
US20110077216A1 (en) * 2009-09-30 2011-03-31 Massachusetts Institute Of Technology Compositions and methods for the treatment of atherosclerosis and other related diseases
JP2011067491A (ja) * 2009-09-28 2011-04-07 Seiko Epson Corp 流体噴射装置
JP2011251156A (ja) * 2004-10-18 2011-12-15 Tyco Healthcare Group Lp 環状接着性構造体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002238909A (ja) * 2001-02-07 2002-08-27 Interventional Technol Inc 脈管治療システム
JP2004533277A (ja) * 2001-02-09 2004-11-04 エンドルミナル セラピューティクス， インコーポレイテッド 壁内療法
JP2004049545A (ja) * 2002-07-19 2004-02-19 Terumo Corp 脈管内血液フィルタ
JP2011251156A (ja) * 2004-10-18 2011-12-15 Tyco Healthcare Group Lp 環状接着性構造体
JP2011067491A (ja) * 2009-09-28 2011-04-07 Seiko Epson Corp 流体噴射装置
US20110077216A1 (en) * 2009-09-30 2011-03-31 Massachusetts Institute Of Technology Compositions and methods for the treatment of atherosclerosis and other related diseases

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9526506B2 (en) 2013-07-29 2016-12-27 Terumo Kabushiki Kaisha Device for treating lumen of living body
US20170216561A1 (en) * 2014-10-13 2017-08-03 Emory University Delivery Devices, Systems and Methods for Delivering Therapeutic Materials
US11712540B2 (en) * 2014-10-13 2023-08-01 Emory University Delivery devices, systems and methods for delivering therapeutic materials
WO2018034922A1 (fr) 2016-08-16 2018-02-22 Ethicon, Inc. Pointes de pulvérisation pour distribution simultanée multidirectionnelle de fluides dissemblables
US10625032B2 (en) 2016-08-16 2020-04-21 Ethicon, Inc. Spray tips for simultaneous multi-directional delivery of dissimilar fluids
EP3788964A1 (fr) 2016-08-16 2021-03-10 Ethicon, Inc. Pointes de pulvérisation pour distribution simultanée multidirectionnelle de fluides dissemblables
WO2021102191A3 (fr) * 2019-11-19 2021-06-24 Papilio Medical, Inc. Système de cathéter destiné à être mis en prise avec un dispositif médical implanté

Similar Documents

Publication Publication Date Title
EP2376174B1 (fr) Dispositif de traitment de lésions durcies
EP1362603B1 (fr) Stent revêtu pour la libération d'un principe actif
JP6082472B2 (ja) ステント
AU2005202037A1 (en) Drug delivery device using microprojections
US20040236414A1 (en) Devices and methods for treatment of stenotic regions
JP2016036730A (ja) 封入薬物組成物およびその使用方法
JP5887348B2 (ja) 治療デバイス
WO2012039291A1 (fr) Feuille adhésive biologique et dispositif de liaison de feuille
CN103974676A (zh) 利用生物可吸收支架的内膜下重通
US9155648B2 (en) Stent delivery system and method using the same
WO2014006738A1 (fr) Dispositif de traitement pour traiter l'intérieur d'une lumière d'organisme
JP2014018493A (ja) 治療デバイスおよび治療方法
JP5848463B2 (ja) カテーテル組立体及びバルーン折り畳み保持方法
US20130066257A1 (en) Design of Interventional Cutting Balloon with Enhanced API Delivery Capability
JP2003093520A (ja) ステント
JP2014014403A (ja) 生体管腔内治療デバイス
JP2013226244A (ja) 治療デバイス及び治療方法
JP4170010B2 (ja) ステント
JP2013226245A (ja) 治療デバイス及び治療方法
JP2016185258A (ja) 医療器具
WO2014006737A1 (fr) Dispositif de traitement destiné à traiter l'intérieur de la lumière d'un organisme
JP2015066146A (ja) 生体管腔治療デバイス
JP2005118123A (ja) ステントおよびその製造方法
JP2013022272A (ja) 治療デバイス
JP2004041704A (ja) ステント

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 12880587

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 12880587

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: JP